Kite and Arcellx prepare to launch Phase III multiple myeloma trial

Kite, a Gilead Company, and Arcellx have announced plans to commence a Phase III clinical trial of anitocabtagene autoleucel (anito-cel), for treating multiple myeloma.

Anito-cel is a B-cell maturation antigen chimeric antigen receptor (BCMA CAR) T-cell therapy.